Merck opens ADVANCE bioanalytical facility at West Point, Pennsylvania

Key highlights
  • Merck is investing approximately $550 million in R&D facilities at ADVANCE and the nearby Spring House Innovation Park as part of a previously announced $70 billion domestic manufacturing and R&D commitment.
  • The ADVANCE facility integrates highly automated robotic systems and advanced digital AI capabilities to streamline analysis of biological samples from clinical development programs.
  • West Point is Merck’s largest integrated research and human health manufacturing site; the company has invested more than $15 billion at the site over the past 35 years and originally acquired it in the 1953 merger with Merck & Sharp & Dohme.
  • Local impact includes West Point being the largest employer in Montgomery County and the seventh largest private employer in Pennsylvania; capital projects have sustained about 800 contracting, engineering and construction jobs and used over $1 billion in services from local architects.
Related project For subscribers
Milestones, plant data, involved companies (owners, investors, licensors, contractors) and news — kept up to date.
Merck ADVANCE bioanalytical research facility, West Point · United States
Operational / Completed
2024-01
2026-10-14

Facility and purpose

Merck inaugurated the ADVANCE research facility on its West Point, Pennsylvania, campus with state and company leaders present for a ribbon‑cutting. ADVANCE is designed to streamline analysis of biological samples from the company’s clinical development programs by integrating highly automated robotic systems and advanced digital AI capabilities.

Investment and network

The company is investing approximately $550 million in R&D facilities at ADVANCE and the nearby Spring House Innovation Park, part of a previously announced $70 billion commitment to domestic manufacturing and R&D. West Point has received more than $15 billion in capital investments over the past 35 years, and many projects were designed in Pennsylvania using over $1 billion in services from local architects.

Site legacy and local impact

The West Point campus, acquired in the 1953 merger with Merck & Sharp & Dohme, is Merck’s largest integrated research and human health manufacturing site. It is the largest employer in Montgomery County and the seventh largest private employer in Pennsylvania; ongoing capital projects have sustained an on‑site workforce of roughly 800 contracting, engineering and construction jobs.

Source: Merck

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time.

Related articles

3 November 2026
Merck launches Phase 3 ENHANCE-3 trial of OHTUVAYRE (ensifentrine) to prevent COPD exacerbations

Randomized Phase 3 will enroll ~2,136 adults on standard COPD therapy to test whether add-on ensifentrine reduces annualized moderate/severe exacerbation rate over 52 weeks.

26 October 2026
Merck: KEYTRUDA monotherapy lowers progression or death risk 43% in dMMR advanced or recurrent endometrial cancer

Phase 3 KEYNOTE‑C93: pembrolizumab alone extended median PFS to 38.2 vs 8.4 months versus platinum doublet; results presented at ESMO and published in The Lancet.

26 October 2026
Merck’s sacituzumab tirumotecan improves survival vs chemotherapy in advanced/recurrent endometrial cancer

Phase 3 TroFuse‑005 showed a 32% lower risk of death and 41% lower risk of progression or death, with a PDUFA target date of June 15, 2027.

22 October 2026
Merck and Moderna present Phase 3 INTerpath‑001: intismeran + KEYTRUDA reduces recurrence in resected stage IIB–IV melanoma

Intismeran plus pembrolizumab cut risk of recurrence or death 42% overall and 58% after six months; distant‑metastasis‑free survival also improved; safety profile consistent.

21 October 2026
Merck’s KEYTRUDA plus Padcev approved by European Commission for perioperative treatment of resectable MIBC

EU clears first PD‑1 inhibitor plus ADC regimen for resectable muscle‑invasive bladder cancer regardless of cisplatin eligibility; phase 3 showed EFS HR 0.53 and OS HR 0.65.